COCP

Cocrystal Pharma, Inc. (COCP) - Q2 2024 10-Q Summary

Business Context and Reporting Period

Cocrystal Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing broad-spectrum antiviral drug candidates for influenza, norovirus, coronavirus, and hepatitis C. This report covers the quarterly period ended June 30, 2024. The company is classified as a non-accelerated filer and a smaller reporting company. As of August 14, 2024, approximately 10,173,790 shares of common stock were outstanding.

Key Financial Metrics

Material Changes vs. Prior Period

• Research & Development (R&D): R&D expenses increased to $4.31 million for Q2 2024 from $2.80 million in Q2 2023. Year-to-date R&D was $7.26 million compared to $6.71 million in the prior year. The increase is attributed to the advancement of the influenza candidate CC-42344 into a Phase 2a clinical trial and the norovirus/coronavirus candidate CDI-988 into a Phase 1 trial.
• General & Administrative (G&A): G&A expenses decreased to $1.14 million for Q2 2024 from $1.54 million in Q2 2023. Year-to-date G&A was $2.35 million compared to $2.74 million in the prior year. The reduction is primarily due to lower litigation expenses.
• Liquidity: Cash and restricted cash decreased from $26.43 million at the beginning of the period to $18.22 million at June 30, 2024, reflecting a net cash burn of $8.21 million for the six-month period.
• Collaborations: The company terminated its collaboration agreement with Merck Sharp & Dohme Corp. effective March 14, 2024, and terminated license agreements with Kansas State University Research Foundation effective March 29, 2024.

Outlook, Risks, and Management Commentary

• Development Progress:
  • Influenza (CC-42344): Enrollment of 78 subjects in the Phase 2a human challenge study was completed in May 2024. In vitro data suggests efficacy against the H5N1 avian flu strain.
  • Norovirus/Coronavirus (CDI-988): Favorable safety and tolerability results were announced in July 2024 from the single-ascending dose (SAD) cohorts of the Phase 1 study in Australia.
• Liquidity Outlook: Management believes current resources ($18.14 million in unrestricted cash) are sufficient to fund operations beyond the next 12 months. However, the company has incurred losses since inception and will require additional capital to continue operations and clinical trials.
• Risks: Key risks include the inability to secure additional financing on acceptable terms, delays in clinical trials, failure to achieve regulatory approval, and the potential for viral mutations rendering candidates ineffective. The company has no products approved for sale and no revenue.
• Capital Resources: The company has an At-The-Market (ATM) offering agreement allowing for the sale of up to $7.25 million of common stock, though no sales were made under this agreement during the six months ended June 30, 2024.

Investor Verification Checklist

• Verify the timeline and interim data readouts for the CC-42344 Phase 2a influenza human challenge study.
• Confirm the safety and pharmacokinetic data from the CDI-988 Phase 1 study in Australia.
• Monitor cash burn rate and the company's ability to extend its runway beyond the projected 12-month horizon without dilutive equity raises.
• Review the status of the terminated Merck collaboration and any potential impact on intellectual property rights or future licensing opportunities.
• Assess the impact of the reduced authorized share count (amended June 27, 2024) on future capital raising flexibility.